Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway.
Adenocarcinoma
/ drug therapy
Animals
Apoptosis
/ drug effects
Caspase 3
/ metabolism
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Humans
Male
Mice, Inbred BALB C
Mice, Nude
Pancreatic Neoplasms
/ drug therapy
Phosphatidylinositol 3-Kinases
/ metabolism
Sesquiterpenes
/ pharmacology
Wnt Signaling Pathway
/ drug effects
Xenograft Model Antitumor Assays
/ methods
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
04
2020
accepted:
15
02
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
10
9
2021
Statut:
epublish
Résumé
Isoalantolactone (IATL) is one of multiple isomeric sesquiterpene lactones and is isolated from inula helenium. IATL has multiple functions such as antibacterial, antihelminthic and antiproliferative activities. IATL also inhibits pancreatic cancer proliferation and induces apoptosis by increasing ROS production. However, the detailed mechanism of IATL-mediated pancreatic cancer apoptosis remains largely unknown. In current study, pancreatic carcinoma cell lines (PANC-1, AsPC-1, BxPC-3) and a mouse xenograft model were used to determine the mechanism of IATL-mediated toxic effects. IATL (20μM) inhibited pancreatic adenocarcinoma cell lines proliferation in a time-dependent way; while scratch assay showed that IATL significantly inhibited PANC-1 scratch closure (P<0.05); Invasion assays indicated that IATL significantly attenuated pancreatic adenocarcinoma cell lines invasion on matrigel. Signal analysis showed that IATL inhibited pancreatic adenocarcinoma cell proliferation by blocking EGF-PI3K-Skp2-Akt signal axis. Moreover, IATL induced pancreatic adenocarcinoma cell apoptosis by increasing cytosolic Caspase3 and Box expression. This apoptosis was mediated by inhibition of canonical wnt signal pathway. Finally, xenograft studies showed that IATL also significantly inhibited pancreatic adenocarcinoma cell proliferation and induced pancreatic adenocarcinoma cell apoptosis in vivo. IATL inhibits pancreatic cancer proliferation and induces apoptosis on cellular and in vivo models. Signal pathway studies reveal that EGF-PI3K-Skp2-Akt signal axis and canonical wnt pathway are involved in IATL-mediated cellular proliferation inhibition and apoptosis. These studies indicate that IATL may provide a future potential therapy for pancreatic cancer.
Sections du résumé
BACKGROUND/AIMS
Isoalantolactone (IATL) is one of multiple isomeric sesquiterpene lactones and is isolated from inula helenium. IATL has multiple functions such as antibacterial, antihelminthic and antiproliferative activities. IATL also inhibits pancreatic cancer proliferation and induces apoptosis by increasing ROS production. However, the detailed mechanism of IATL-mediated pancreatic cancer apoptosis remains largely unknown.
METHODS
In current study, pancreatic carcinoma cell lines (PANC-1, AsPC-1, BxPC-3) and a mouse xenograft model were used to determine the mechanism of IATL-mediated toxic effects.
RESULTS
IATL (20μM) inhibited pancreatic adenocarcinoma cell lines proliferation in a time-dependent way; while scratch assay showed that IATL significantly inhibited PANC-1 scratch closure (P<0.05); Invasion assays indicated that IATL significantly attenuated pancreatic adenocarcinoma cell lines invasion on matrigel. Signal analysis showed that IATL inhibited pancreatic adenocarcinoma cell proliferation by blocking EGF-PI3K-Skp2-Akt signal axis. Moreover, IATL induced pancreatic adenocarcinoma cell apoptosis by increasing cytosolic Caspase3 and Box expression. This apoptosis was mediated by inhibition of canonical wnt signal pathway. Finally, xenograft studies showed that IATL also significantly inhibited pancreatic adenocarcinoma cell proliferation and induced pancreatic adenocarcinoma cell apoptosis in vivo.
CONCLUSIONS
IATL inhibits pancreatic cancer proliferation and induces apoptosis on cellular and in vivo models. Signal pathway studies reveal that EGF-PI3K-Skp2-Akt signal axis and canonical wnt pathway are involved in IATL-mediated cellular proliferation inhibition and apoptosis. These studies indicate that IATL may provide a future potential therapy for pancreatic cancer.
Identifiants
pubmed: 33661942
doi: 10.1371/journal.pone.0247752
pii: PONE-D-20-07339
pmc: PMC7932101
doi:
Substances chimiques
Sesquiterpenes
0
isoalantolactone
BYH07P620U
Caspase 3
EC 3.4.22.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0247752Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Biomed Pharmacother. 2018 Sep;105:887-898
pubmed: 30021382
Cancer Lett. 2017 Apr 10;391:38-49
pubmed: 28093284
Anticancer Res. 2014 Oct;34(10):5375-80
pubmed: 25275031
Clin Chim Acta. 2019 Jan;488:226-234
pubmed: 30452897
Mol Cancer Ther. 2019 Feb;18(2):301-311
pubmed: 30404927
J Cell Physiol. 2019 Feb;234(2):1237-1247
pubmed: 30191954
Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):739-47
pubmed: 24882381
Ann Oncol. 2012 Oct;23 Suppl 7:vii33-40
pubmed: 22997452
Int J Mol Sci. 2018 Oct 18;19(10):
pubmed: 30340359
Int J Biochem Cell Biol. 2019 Feb;107:38-52
pubmed: 30529656
BMC Cancer. 2017 Mar 24;17(1):216
pubmed: 28340556
Neoplasia. 2017 Apr;19(4):288-300
pubmed: 28284058
Front Oncol. 2019 Apr 05;9:246
pubmed: 31024848
Int J Biol Sci. 2012;8(4):533-47
pubmed: 22532787
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220
pubmed: 30718832
Vascul Pharmacol. 2018 Nov;110:16-23
pubmed: 29969688
Expert Opin Ther Targets. 2014 Jun;18(6):611-5
pubmed: 24702624
Tumour Biol. 2014 Oct;35(10):9807-13
pubmed: 24986570
Oncogene. 2018 Mar;37(13):1759-1774
pubmed: 29343851
Oncotarget. 2019 Feb 1;10(10):1056-1069
pubmed: 30800218
J Exp Clin Cancer Res. 2018 Dec 12;37(1):309
pubmed: 30541589
J Cell Mol Med. 2008 Dec;12(6B):2823-35
pubmed: 18298655
Cell Death Dis. 2015 Jan 15;6:e1599
pubmed: 25590809
Toxicol In Vitro. 2010 Sep;24(6):1599-609
pubmed: 20600805
Curr Top Med Chem. 2019;19(23):2176-2186
pubmed: 31456520
CA Cancer J Clin. 2013 Sep;63(5):318-48
pubmed: 23856911
Int J Oncol. 2017 Jan;50(1):232-240
pubmed: 27878249
Sci Signal. 2019 Jul 09;12(589):
pubmed: 31289213
Toxicol Sci. 2013 Oct;135(2):380-9
pubmed: 23897984
Pancreas. 2019 Sep;48(8):1003-1014
pubmed: 31404031
J Hepatol. 2013 Oct;59(4):830-41
pubmed: 23665184
Pharmacol Ther. 2015 Feb;146:1-11
pubmed: 25172549
Sci Rep. 2018 Feb 6;8(1):2487
pubmed: 29410485
Cancers (Basel). 2019 Dec 09;11(12):
pubmed: 31835379
Tumour Biol. 2016 Sep;37(9):12455-12464
pubmed: 27333990
Am J Transl Res. 2019 Feb 15;11(2):991-997
pubmed: 30899398
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1618-1624
pubmed: 30060948
FEBS J. 2019 Sep;286(18):3510-3539
pubmed: 31330086
Cancer Res. 2019 Mar 15;79(6):1019-1031
pubmed: 30808672
Int J Mol Sci. 2018 Dec 30;20(1):
pubmed: 30598026
Clin J Gastroenterol. 2019 Aug;12(4):285-291
pubmed: 30788774
Nat Prod Res. 2020 Sep;34(17):2539-2544
pubmed: 30661396
Int J Oncol. 2011 Jan;38(1):219-25
pubmed: 21109943
Cell Rep. 2017 Aug 1;20(5):1148-1160
pubmed: 28768199
Nat Commun. 2018 Nov 9;9(1):4728
pubmed: 30413706
Biomed Pharmacother. 2019 Feb;110:473-481
pubmed: 30530050
Mol Med Rep. 2018 Mar;17(3):3527-3536
pubmed: 29286105
Semin Cancer Biol. 2019 Aug;57:10-18
pubmed: 31009762